A dysregulation of ACE2 can theoretically also lead to decreased cardioprotection in the context of myocardial involvement following pulmonary and circulatory haemodynamic compromise in patients who develop COVID-19 with severe critical conditions [85,86]. This evidence concerns the gene ACE2 and COVID-19.